Banos V, Gómez J, García A, Ruiz J, Alvarez R, Lorenzo M, Canteras M, Valdés M
Department of Internal Medicine (Unit of Infectious Diseases), Hospital Universitario Virgen Arrixaea, EL Palmar, Spain.
Respiration. 1997;64(3):220-3. doi: 10.1159/000196674.
We conducted a prospective randomized study to assess the effect of thymostimulin in patients with long-standing chronic obstructive pulmonary disease (COPD) during a 1-year follow-up. A total of 38 patients in the intervention group and 40 in the control group received standard treatment for COPD. Patients in the intervention group were also given thymostimulin intramuscularly (1 mg/kg day for the 1st week followed by once a week for 6 months). At the end of the study period, patients treated with thymostimulin showed a statistically significant lower number of exacerbations and hospital admissions as compared with controls. However, there were no changes in the number of patients with severe or moderate impairment of respiratory function throughout the study period. No significant differences were found by Multitest or in serum concentrations of immunoglobulins and T-cell subsets before and after thymostimulin treatment. We conclude that treatment with thymostimulin is effective in the prevention of COPD exacerbations acting on the cellular immune response involved in bronchopulmonary defense.
我们进行了一项前瞻性随机研究，以评估胸腺刺激素对长期慢性阻塞性肺疾病（COPD）患者在1年随访期间的影响。干预组38例患者和对照组40例患者接受了COPD的标准治疗。干预组患者还接受了胸腺刺激素肌肉注射（第1周1mg/kg/天，随后6个月每周1次）。在研究期结束时，与对照组相比，接受胸腺刺激素治疗的患者急性加重和住院次数在统计学上显著降低。然而，在整个研究期间，呼吸功能严重或中度受损的患者数量没有变化。胸腺刺激素治疗前后，通过多重检测或免疫球蛋白和T细胞亚群的血清浓度均未发现显著差异。我们得出结论，胸腺刺激素治疗可有效预防COPD急性加重，作用于支气管肺防御中涉及的细胞免疫反应。
